Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Further Reading from MarketBeat Media
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?Reported by Jeffrey Neal Johnson. Posted: 4/7/2026. In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking. Abbott Laboratories' stock price recently touched its 52-week low, closing just above $100 in the last trading days of March. This sharp downturn has left many wondering whether the foundation of this industry leader is cracking.
Barron's calls the SpaceX IPO 'the capital markets event of the century' - and with an estimated $625 billion in new wealth potentially minted overnight, it's hard to argue otherwise. Elon has already filed the paperwork, with the IPO expected as soon as June 15th.
But history shows the biggest gains from major IPOs tend to come before the stock goes public - not after. A pre-IPO SpaceX trade plan outlines exactly how to position ahead of what could be the largest IPO event in market history. Watch the Pre-IPO SpaceX Trade Plan before the window closes
Key Points
Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment. Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders. Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion. - Special Report: Have $500? Invest in Elon’s AI Masterplan
A deeper look into Abbott Laboratories' situation reveals a potential disconnect between market sentiment and operational reality, raising a critical question: Is the market’s pessimism justified, or has a significant value opportunity emerged for long-term investors? Separating the Signal From the NoiseStocks rarely fall without reason, and Abbott's recent decline stems from two distinct pressures. The first is an internal headwind from its Nutrition segment. Abbott Laboratories' fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in that division, primarily due to market-share losses in its U.S. pediatric business and pricing dynamics that constrained volume. Management has been transparent about the challenge and outlined a clear turnaround plan. CEO Robert B. Ford described price and promotion initiatives and a pipeline of at least eight new product launches in 2026 intended to reignite volume growth, with a forecasted return to growth in the second half of the year. The second factor is external and broader in scope. The market has been undergoing a significant rotation of capital: in periods of economic optimism, investors often shift funds away from stable, defensive sectors like the healthcare sector into higher-beta areas such as artificial intelligence (AI) and the energy sector in pursuit of faster returns. That broad trend has pressured many fundamentally sound healthcare names, including Abbott, for reasons largely unrelated to their individual performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile the Nutrition segment navigates a short-term recovery, Abbott Laboratories' core remains exceptionally strong, led by its largest and most profitable division: Medical Devices. That segment is accelerating, posting 10.4% organic growth in the most recent quarter. Abbott’s diversified model provides a powerful counterbalance to the isolated weakness in nutrition; the company’s true health is most evident in these higher-performing areas.
Medical Devices: The Medical Devices business is gaining momentum, driven by market-leading innovation in critical care areas. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) continues to be a growth phenomenon. This product line, which allows users to track glucose without routine fingersticks, generated over $7.5 billion in sales in 2025 and remains a primary driver of Abbott's sustained success. Cardiovascular Leadership: Abbott is also a dominant force in cardiovascular care. Its Electrophysiology business grew at a double-digit rate, while Structural Heart posted strong organic growth of 8.7%. That strength comes from best-in-class products such as MitraClip and TriClip, which offer minimally invasive solutions for valve repair, and a pipeline of innovations that includes the recently FDA-approved Volt PFA System for treating atrial fibrillation. Abbott is not relying solely on its existing portfolio. The company is making a major strategic move to secure future growth through the acquisition of Exact Sciences. Exact Sciences is a leader in cancer screening and diagnostics, best known for its non-invasive colon cancer test, Cologuard. The deal would immediately position Abbott as a leader in the rapidly expanding, multi-billion-dollar market for cancer diagnostics, adding a new, high-growth vertical poised to contribute meaningfully to revenue for years to come. That bullish outlook is shared by professional analysts. Wall Street maintains a Moderate Buy consensus rating on the stock. The average 12-month price target is $135.47, implying potential upside of more than 30% from current levels and signaling that many analysts view the stock as undervalued. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on building a reliable income stream, Abbott’s dividend is a compelling feature. Abbott Laboratories is a member of the S&P 500 Dividend Kings, an exclusive group of companies that have increased their dividend for at least 50 consecutive years. That track record demonstrates a firm commitment to returning capital to shareholders through all market cycles. The recent decline in Abbott’s stock price has a direct, positive effect for new investors: a higher dividend yield. At current levels, Abbott offers a yield of about 2.5%, letting investors lock in a higher rate of income from this historically reliable payer. The dividend also appears secure: the payout ratio is roughly 68% of earnings, and the dividend represents only about 37% of cash flow, indicating Abbott generates more than enough cash to cover payments with room for future increases. A Disconnect Between Price and ValueCurrent market sentiment around Abbott Laboratories appears disconnected from the company's operational reality. Temporary headwinds in a single division and broader market rotation have depressed the stock price, even as Abbott's fundamental growth engines accelerate. Its dominant Medical Devices division continues to deliver strong results, the dividend remains a bedrock of reliability, and catalysts like the Exact Sciences acquisition could add meaningful growth. For investors with a long-term perspective, the current valuation presents a notable gap between market price and fundamental value, offering an opportunity that deserves serious consideration. |
